PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.04%
R&D growth while TRAW reduces spending. John Neff would investigate strategic advantage.
21.61%
G&A growth above 1.5x TRAW's 5.61%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.65%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
22.65%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.49%
D&A change of 3.49% while TRAW maintains D&A. Bruce Berkowitz would investigate efficiency.
-23.08%
EBITDA decline while TRAW shows 10.53% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.65%
Operating income decline while TRAW shows 10.53% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-58.12%
Other expenses reduction while TRAW shows 466.67% growth. Joel Greenblatt would examine advantage.
-23.20%
Pre-tax income decline while TRAW shows 11.24% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.20%
Net income decline while TRAW shows 11.40% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-16.67%
EPS decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
-22.50%
Diluted EPS decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
5.52%
Share count change of 5.52% while TRAW is stable. Bruce Berkowitz would verify approach.
0.56%
Diluted share change of 0.56% while TRAW is stable. Bruce Berkowitz would verify approach.